RedHill Biopharma (RDHL) Other Non-Current Liabilities (2011 - 2016)

RedHill Biopharma (RDHL) has 6 years of Other Non-Current Liabilities data on file, last reported at $1.1 million in Q4 2016.

• Other Non-Current Liabilities for Q4 2016 came in at $1.1 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2016 was $1.1 million (changed 0.0% YoY), and the FY2016 annual result was $1.1 million, changed 0.0% from the prior year.
• Other Non-Current Liabilities held at $1.1 million in Q4 2016 per RDHL's latest filing, from $1.1 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $3.3 million in Q4 2012 and troughed at $1.1 million in Q1 2015.
• A 5-year average of $1.7 million and a median of $1.5 million in 2014 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2012 and 2014: Other Non-Current Liabilities advanced 21.85% in 2012, then sank 52.72% in 2014.
• A 5-year view of Other Non-Current Liabilities shows it stood at $3.3 million in 2012, then sank by 42.96% to $1.9 million in 2013, then decreased by 18.16% to $1.5 million in 2014, then tumbled by 30.82% to $1.1 million in 2015, then changed by 0.0% to $1.1 million in 2016.
• Business Quant data shows RDHL's Other Non-Current Liabilities at $1.1 million in Q4 2016, $1.1 million in Q3 2016, and $1.1 million in Q2 2016.